SPOTLIGHT: Indian pharmas woo Romania's LaborMed

Three Indian pharma companies--Shreya Lifesciences, Dr. Reddy's Laboratories, and Lupin--are in the race to buy Romania's LaborMed, which markets some 80 products in that country. The price is expected to be around $100 million. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.